Skip to Main Content

Paper Details

Differential impact of RB status on E2F1 reprogramming in human cancer.
J Clin Invest
73
2018
E2F1, E2F1 cistrome, RB, RB-deficient tumors, advanced prostate cancer, cancer, cancers, cell, human, patients, protumorigenic transcriptional networks, retinoblastoma, transcription factor E2F1, tumor, tumor types
Author NameAffiliation
Johan LindbergKarolinska Institutet
Henrik Gr??nbergKarolinska Institutet
Henrik Gr??nbergKarolinska Institutet
Luc DirixUniversity of Antwerp
Luc DirixGZA Hospitals Sint-Augustinus
Tapio VisakorpiBioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere and Fimlab Laboratories, Tampere University Hospital
Felix Y Fengand Medicine and Helen Diller Family Comprehensive Cancer Center
Johann S de BonoDivision of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research
Francesca DemichelisUniversity of Trento
Francesca DemichelisEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian Hospital
Francesca DemichelisUniversity of Trento
Francesca DemichelisEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian Hospital
Mark A RubinEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian Hospital
Mark A RubinSandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Mark A RubinEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York Presbyterian Hospital
Mark A RubinSandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Myles BrownCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
Myles BrownDana-Farber Cancer Institute
  • 1 - 18

Datasets